期刊文献+

血管紧张素Ⅱ1型受体拮抗剂对高血压患者动脉弹性及脉压的影响 被引量:8

Clinical study of Irbesartan on improving arterial elasticity and pulse pressure in essential hypertensives
下载PDF
导出
摘要 目的观察厄贝沙坦对脉压(PP)≥60 mm Hg(1 mm Hg=0.133 kPa)高血压患者的动脉弹性功能、反射波及PP的影响。方法选取符合入选条件的原发性高血压患者30例,男13例、女17例,平均年龄为(65.2±8.5)岁(51~83岁),随机分成治疗组和对照组,分别给予厄贝沙坦(150 mg/d)和安慰剂治疗3个月。结果与治疗前相比,对照组治疗后中心和肱动脉收缩压、舒张压及PP轻度下降,但差异无显著性(P>0.05);而治疗组显著下降(P<0.05),治疗组的降幅均显著高于对照组(P值分别<0.05和0.01)。治疗后,治疗组的反射波增强压(AP)和增强指数(A1)明显下降(P<0.01),颈-股动脉脉搏波传导速度(CF-PWV)显著变慢(P<0.01),降幅显著高于对照组;大、小动脉弹性功能指数(Cl、C_2)值均显著增加(P值分别<0.05和0.01),增幅显著高于对照组。分别以C_1和CF-PWV变化为应变量,收缩压、舒张压降幅为自变量行多元线形回归分析,决定系数(R2)为0.486及0.384(P<0.05)。结论厄贝沙坦可明显改善PP≥60mm Hg高血压患者的大、小动脉弹性,减弱外周波反射,缩小PP。 Objectives To investigate the effects of Irbesartan on arterial elasticity, wave reflection and pulse pressure in essential hypertensives with pulse pressure of 60 mm Hg(1 mm Hg=0. 133 kPa) or more. Methods Thirty elderly essential hypertensives with pulse pressure of 60 mm Hg or more [13 males and 17 females, average age (65.2±8. 5)years] were enrolled and divided into two groups in equal number (treatment and controlled groups). The treatment group received Irbesartan (150 mg/d) individually and the controlled group with placebo therapy for 12 weeks. Brachial blood pressure was measured by standardized mercury cuff sphygnomanometer. Automatic pulse wave velocity (PWV) measurement system and DO-2020 Arterial Pulse Contour Instrument were applied to examine the carotid-femoral PWV (CF-PWV) and the large and small arterial elastic indexes (C1 and C2 ) respectively. Central arterial pressure, augmentation pressure and augmentation index (AI) were acquired by using the radial pulse wave analysis system. Results After three months treatment, the controlled group showed insignificant changes of pulse pressure and artery elasticity index. The treatment group, after excluding the placebo effect, showed significant increase of C1 and C2 , CF-PWV slowed down obviously; both augmentation pressure and AI dropped significantly; together with significant decrease of peripheral and central systolic pressure, diastolic pressure and pulse pressure. The decreased blood pressure could partialy explain the improvement of large artery elasticity. Conclusion Irbesartan improves the small and large arterial elasticity, attenuates the wave reflex amplitude and reduces pulse pressure in the essential hypertensives with pulse pressure of 60 mmHg or more. (Shanghai Med J, 2006, 29:636-639)
出处 《上海医学》 CAS CSCD 北大核心 2006年第9期636-639,共4页 Shanghai Medical Journal
关键词 厄贝沙坦 脉压 脉搏波传导速度 反射波 大小动脉弹性指数(C1和C2) Irbesartan Pulse pressure Pulse wave velocity(PWV) Wave reflection Large and small arterial elasticity index(C1 and C2 )
  • 相关文献

参考文献13

  • 1Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report.JAMA,2003,289:2560-2572.
  • 2Asmar R,Benetos A,Topouchian J,et al.Assessment of arterial distensibility by automatic pulse wave velocity measurement.Validation and clinical application studies.Hypertension,1995,26:485-490.
  • 3丁跃有,张维忠.高血压动脉弹性功能无创性评价[J].高血压杂志,2002,10(6):503-504. 被引量:28
  • 4Cohn JN,Finkelstein S,McVeigh G,et al.Noninvasive pulse wave analysis for the early detection of vascular disease.Hypertension,1993,26:503-508.
  • 5Chen CH,Nevo E,Fetics B,et al.Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure:validation of generalized transfer function.Circulation,1997,95:1827-1836.
  • 6Klemsdal TO,Moan A,Kjeldsen SE.Effect of selective angiotensin Ⅱ typer 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension.Blood Press,1999,8:214-219.
  • 7Asmar R,Gosse P,Topouchian J,et al.Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.J Renin Angiotensin Aldosterone Syst,2002,3:176-180.
  • 8Mahmud A,Feely J.Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin Ⅱ receptor blockade in resistant hypertension.J Hum Hypertens,2000,14:541-546.
  • 9Prasad A,Tupas-Habib T,Schenke WH,et al.Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis.Circulation,2000,101:2349-2354.
  • 10Hornig B,Landmesser U,Kohler C,et al.Comparative effect of ace inhibition and angiotensin Ⅱ type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease:role of superoxide dismutase.Circulation,2001,103:799-805

二级参考文献29

  • 1Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752.
  • 2Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587.
  • 3Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003.
  • 4Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860.
  • 5Circulation, 2002;106:672.
  • 6Parving HH,Lehnert H,Brochner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med, 2001,345:870-878.
  • 7Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001 Sep 20;345(12):861-869.
  • 8Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens, 2003,21:875-886.
  • 9ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Groop. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lo
  • 10Wong M,Staszewsky L,Latini R,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.J Am Coll Cardiol, 2002,40:970-975.

共引文献87

同被引文献103

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部